Is Alzheimers Drug Discovery Foundation Legit?

The Alzheimers Drug Discovery Foundation (ADDF) demonstrates a strong commitment to its program services, with a significant portion of its expenses directed towards its mission. For instance, in 2023, 85% of its total expenses were allocated to program services, indicating efficient use of donor funds for its core activities. The organization has also shown substantial growth in assets, from $19.3 million in 2014 to over $324 million in 2023, suggesting robust financial management and fundraising success. However, there have been periods where expenses exceeded revenue, such as in 2023 where expenses were $61.9 million against $37.7 million in revenue, and in 2019 where expenses were $32.4 million against $22.7 million in revenue. This indicates reliance on prior year surpluses or investment income to cover operational costs in some periods. ADDF's financial health appears generally strong, supported by substantial assets and a history of significant revenue generation, particularly the $254 million in revenue reported in 2022. The consistent reporting of 0% officer compensation across all available filings is a notable aspect of its transparency and financial practices, suggesting that executive leadership is not directly compensated through the organization's funds, or that compensation is reported differently. This practice, if accurately reflecting no direct compensation, could be seen as a positive indicator of resource allocation towards the mission. Overall, ADDF exhibits a healthy financial position with a clear focus on program spending. While there are fluctuations in annual revenue and expenses, the long-term trend shows significant asset growth and a consistent dedication to its mission. The absence of reported officer compensation is a unique and positive transparency feature, contributing to a favorable view of its financial stewardship.